EMBECTA CORP. (EMBC) Current Ratio
- Current ratio · latest quarter: Value 1.68×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.68× | Current assets / current liabilities. $705.10M ÷ $419.80M ≈ 1.68× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 705.10M USD | Assets, Current |
| Current obligations | 419.80M USD | Liabilities, Current |
| Cash and equivalents | 214.70M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 182.20M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 214.20M USD | Inventory, Net |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | 139.40M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $705.10M | $419.80M | $214.70M | (m) | $182.20M | $214.20M | (m) | $139.40M | 1.68× |
| 2026-03-31 | $608.10M | $247.30M | $184.90M | (m) | $147.10M | $192.60M | (m) | $9.50M | 2.46× |
| 2025-12-31 | $620.20M | $234.70M | $201.30M | (m) | $159.20M | $181.80M | (m) | $9.50M | 2.64× |
| 2025-09-30 | $631.40M | $261.50M | $225.50M | (m) | $145.60M | $178.60M | (m) | $9.50M | 2.41× |
| 2025-06-30 | $681.50M | $275.50M | $230.60M | (m) | $182.80M | $189.90M | (m) | $9.50M | 2.47× |
| 2025-03-31 | $643.40M | $259.30M | $209.30M | (m) | $185.60M | $169.20M | (m) | $9.50M | 2.48× |
| 2024-12-31 | $667.20M | $298.20M | $210.00M | (m) | $180.90M | $169.10M | (m) | $9.50M | 2.24× |
| 2024-09-30 | $761.00M | $374.00M | $267.50M | (m) | $193.00M | $171.50M | (m) | $9.50M | 2.03× |
| 2024-06-30 | $781.10M | $370.70M | $275.10M | (m) | $171.80M | $185.60M | (m) | $9.50M | 2.11× |
| 2024-03-31 | $710.00M | $310.40M | $299.80M | (m) | $123.70M | $153.20M | (m) | $9.50M | 2.29× |
| 2023-12-31 | $719.50M | $326.60M | $298.70M | (m) | $96.10M | $149.20M | (m) | $9.50M | 2.20× |
| 2023-09-30 | $749.10M | $353.50M | $326.30M | (m) | $16.70M | $152.10M | (m) | $9.50M | 2.12× |
| 2023-06-30 | $787.50M | $385.80M | $317.40M | (m) | $21.10M | $170.30M | (m) | $9.50M | 2.04× |
| 2023-03-31 | $756.30M | $357.70M | $346.40M | (m) | $19.10M | $157.60M | (m) | $9.50M | 2.11× |
| 2022-12-31 | $761.70M | $370.30M | $385.20M | (m) | $19.90M | $143.40M | (m) | $9.50M | 2.06× |
| 2022-09-30 | $664.70M | $301.00M | $330.90M | (m) | $22.20M | $122.80M | (m) | $9.50M | 2.21× |
| 2022-06-30 | $580.60M | $228.50M | $292.30M | (m) | $22.20M | $130.30M | $64.30M | $9.50M | 2.54× |
| 2022-03-31 | $426.50M | $168.90M | $264.30M | (m) | $15.20M | $122.40M | $50.80M | $9.50M | 2.53× |
| 2021-12-31 | $258.30M | $159.10M | $0.00 | (m) | $118.30M | $119.10M | $58.10M | (m) | 1.62× |
| 2021-09-30 | $291.80M | $164.00M | $0.00 | (m) | $150.60M | $118.00M | (m) | $0.00 | 1.78× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |